InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,880.00
(
-2.30%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
71.25
(
0.00%
)
Bitcoin
90,751.15
(
0.19%
)
Post# of 158400
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Krisandtilly

Send PM Follow Ignore
Followers 21
Posts 1744
Boards Moderated 0
Alias Born 03/12/2013

Krisandtilly

Re: None

Monday, 09/08/2014 7:06:06 AM

Monday, September 08, 2014 7:06:06 AM

Post# of 158400
The FDA is treating BMSN's ind as a new class of drug that may explain the new dept they developed for such and part of the delay in review process that's the system and not the fault of BMSN or RGBP ...thus I doubt it'll be a long time seeing the spotlight is now on fighting cancer with the immune system IMO we will hear very soon from the FDA .

http://mobile.bloomberg.com/news/2014-09-04/merck-wins-u-s-approval-for-melanoma-immunotherapy.html
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up